Skip to main content
Rachel Grisham, MD, Oncology, West Harrison, NY

RachelGrishamMD

Oncology West Harrison, NY

Gynecologic Cancer, Hematologic Oncology

Associate Attending, Memorial Sloan Kettering Cancer Center & Weill Cornell Medical College; Section Head of Ovarian Cancer; Director Gynecologic Medical Oncology MSKCC Westchester

Overview of Dr. Grisham

Dr. Rachel Grisham is an oncologist in West Harrison, NY and is affiliated with Memorial Sloan Kettering Cancer Center. She received her medical degree from Duke University School of Medicine and has been in practice 11 years. Dr. Grisham accepts several types of health insurance, listed below. She is one of 494 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. She has more than 80 publications and over 500 citings.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 2006 - 2009
  • Duke University School of Medicine
    Duke University School of MedicineClass of 2006

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • NY State Medical License
    NY State Medical License 2009 - 2026
  • CT State Medical License
    CT State Medical License 2023 - 2025
  • NJ State Medical License
    NJ State Medical License 2019 - 2025
  • NC State Medical License
    NC State Medical License 2020 - 2022
  • MA State Medical License
    MA State Medical License 2008 - 2009
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Low Grade Ovarian Carcinoma: Fitting the Square Peg into the Round Hole 
    ASCO Annual Meeting 2019 - Chicago, IL - 5/3/2019
  • Gynecologic Cancer 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/4/2019

Press Mentions

  • Updated Data from Part a of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib
    Updated Data from Part a of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and DefactinibMay 25th, 2023
  • Targeting Progesterone in Hormonally Responsive Ovarian Cancer
    Targeting Progesterone in Hormonally Responsive Ovarian CancerDecember 10th, 2019
  • Context Therapeutics and World-Renowned Cancer Center Announce a Phase 2 Trial for Apristor® in Progesterone Receptor Positive Gynecological Cancers
    Context Therapeutics and World-Renowned Cancer Center Announce a Phase 2 Trial for Apristor® in Progesterone Receptor Positive Gynecological CancersMay 2nd, 2019
  • Join now to see all

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    Empire BCBS HMO
    Empire BCBS PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    MVP Healthcare PPO
    Oxford Health Freedom
    Oxford Health Liberty
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment